Targacept

To see an up-to date selection of historical analyses and insights on Targacept, visit our new, dynamically updated Company Summary report pages for Targacept.

As a Guest User, you will have FREE access to a selection of historical analyses and insights from EvaluatePharma®.

How to access FREE content

  • Search the content using the search box at the top of every page
  • Browse content by Company, Product, Generic Name, Therapeutic Category or Indication using the "Browse By" link from the navigation bar
  • Create Peer Groups to compare Companies using the "Peer Groups" link from the navigation bar

Register for FREE to access even more content including 2007 Product Sales and Rankings.

A small selected sample of reports and related news headlines for Targacept are available below. Free sample reports are also available for other Companies.

To find out how you can access more detailed information on Targacept, or on any other Company covered by EvaluatePharma® Contact Us today.

NEWS - Selected Product News Headlines (as of 11 June 2008)
Targacept Initiates Phase 2 Study of TC-5619 in Cognitive Dysfunction in Schizophrenia   (Targacept)   (Invalid Date)
AstraZeneca gives late stage pipeline another boost   (AstraZeneca)   (Invalid Date)
Targacept provides reasons to be happy with depression drug data   (Targacept)   (Invalid Date)
Targacept Presents Data from Highly Successful Phase 2b Trial of TC-5214 as Augmentation Treatment for Major Depressive Disorder   (Targacept)   (Invalid Date)
Event – Targacept hoping to be as pleasing second time round   (Targacept)   (Invalid Date)
Data to be Presented on Multiple Targacept NNR Therapeutics at Society for Neuroscience Satellite Symposium   (Targacept)   (Invalid Date)
Targacept success could reignite interest in nicotinic drugs   (Targacept)   (Invalid Date)
Targacept’s TC-5214 Achieves All Primary and Secondary Outcome Measures in Phase 2b Trial as Augmentation Treatment for Major Depressive Disorder   (Targacept)   (Invalid Date)
AstraZeneca's partnering decisions boosts Targacept while MAP heads for the door   (AstraZeneca)   (Invalid Date)
AstraZeneca to Advance AZD3480 in ADHD   (AstraZeneca)   (Invalid Date)
Targacept Announces Decision by AstraZeneca to Advance AZD3480 Program in ADHD   (Targacept)   (Invalid Date)
Targacept’s positive ADHD drug data gets investors' attention   (Targacept)   (Invalid Date)
Targacept Announces Positive Top-Line Results from Phase II Study of AZD3480 in Adult ADHD   (Targacept)   (Invalid Date)
Targacept Initiates Phase 2 Study of TC-5214 in Patients with Resistant Hypertension   (Targacept)   (Invalid Date)
Targacept Provides Update on TC-6499 and Pain Program in GlaxoSmithKline Alliance   (Targacept)   (Invalid Date)

EvaluatePharma® provides historic and forecast sales from 1986 to 2012 for worldwide and US Rx (prescription drugs) and OTC drugs. EvaluatePharma® analysts continuously update company models from SEC filings, annual reports, investor/analyst presentations, company press releases, FDA and USPTO. Consensus forecasts for marketed and emerging products are built-up using recent research reports from top equity analysts.

Analyse pharma and biotech products by market status or development phase (e.g., preclinical, phase I, phase II, phase III, filed, approved, withdrawn, disposed etc), therapeutic category, product sourcing strategy, patent expiry and patent life remaining, originator, technology, indication, pharmacological class, deal dates, deal types and partners, launch dates, FDA approval data and new molecular entity (NME) age - plus many more data items and analytics unique to EvaluatePharma®.

Aggregations of these measures at a high-level means that companies may be ranked against each other on items such as: market capitalization, patent risk, R&D spend, freshness index, sales strategy (inlicensed vs organic sales), sales by therapy area or technology and various other concentration measures. These aggregations make EvaluatePharma® ideal for competitive benchmarking, ranking and Peer Group analysis.

Note: When a merger or acquisition is agreed, a virtual merged Company will be added to the list of available Company reports. Any information presented for a virtual merged company is for illustrative purposes, only.